Is Mirum Pharmaceuticals About to Soar in 2026?
Mirum Pharmaceuticals' (NASDAQ: MIRM) share price has more than doubled over the last 12 months. Is this biotech stock about to soar again in 2026? I think so – for two key reasons.
In several important ways, Mirum is at an inflection point. It achieved positive cash flow from operations in 2025. That's a significant milestone for any small biotech company.
Mirum won two approvals from the U.S. Food and Drug Administration (FDA) last year. In February, the agency gave Ctexli a thumbs-up for the treatment of cerebrotendinous xanthomatosis (CTX), a rare genetic disorder of bile acid synthesis. The FDA also approved a tablet formulation of Livmarli in April for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) and Progressive Familial Intrahepatic Cholestasis (PFIC), both rare liver diseases.
Source Fool.com
Progressive Corp. Aktie
Die Community bevorzugt Progressive Corp., mit deutlich mehr Buy- (41) als Sell-Einschätzungen (3).
Mit einem Kursziel von 280 € für Progressive Corp. könnte der aktuelle Kurs von 171.14 € um mehr als 50% steigen.
